Last reviewed · How we verify
Novel dose adjustment of Alutard SQ
Alutard SQ is an allergen immunotherapy product that desensitizes patients to specific allergens through gradual dose escalation.
Alutard SQ is an allergen immunotherapy product that desensitizes patients to specific allergens through gradual dose escalation. Used for Allergic rhinitis and asthma caused by specific allergens (e.g., pollen, dust mites, animal dander).
At a glance
| Generic name | Novel dose adjustment of Alutard SQ |
|---|---|
| Sponsor | Beijing Tongren Hospital |
| Drug class | Allergen immunotherapy |
| Modality | Biologic |
| Therapeutic area | Immunology / Allergy |
| Phase | FDA-approved |
Mechanism of action
Alutard SQ works by administering increasing doses of allergen extract to induce immune tolerance and reduce allergic responses. The novel dose adjustment refers to an optimized dosing schedule that improves efficacy and safety compared to standard protocols. This approach modulates T-cell and B-cell responses to allergens, reducing IgE-mediated reactions and promoting regulatory T-cell development.
Approved indications
- Allergic rhinitis
- Allergic asthma
- Atopic dermatitis
Common side effects
- Local injection site reactions (erythema, swelling, pruritus)
- Systemic allergic reactions
- Anaphylaxis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Novel dose adjustment of Alutard SQ CI brief — competitive landscape report
- Novel dose adjustment of Alutard SQ updates RSS · CI watch RSS
- Beijing Tongren Hospital portfolio CI